{ "schemaVersion": "deck-intelligence.v1", "id": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "slug": "5062b9a9257606648ea145bccd66e04d", "title": "Nuvalent | Investor Presentation Deck | 41 slides", "subtitle": "Nuvalent · 2024-01", "author": "Nuvalent", "date": "2024-01-01 00:00:00", "pageCount": 41, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de076-b7ca-70fb-95b8-5a74e3aefffe", "slug": "5062b9a9257606648ea145bccd66e04d", "title": "Nuvalent | Investor Presentation Deck | 41 slides", "rawTitle": "Nuvalent | Investor Presentation Deck | 41 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "authorDisplay": "Nuvalent", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2024-01__nuvalent__investor-pres__5062b9a9.pdf", "sourceUrl": "https://www.slidebook.io/company/nuvalent/presentation/5062b9a9257606648ea145bccd66e04d/", "sourceDate": "2024-01-08 00:00:00", "presentationDate": "2024-01-01 00:00:00", "ingestedAt": "2026-04-30 22:16:10.030933+00", "status": "ready", "pageCount": 41, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2024-01__nuvalent__investor-pres__5062b9a9", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 41, "pagesIndexed": 41, "pagesWithImages": 41, "pagesWithMetadata": 41, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 197, "chartCount": 19, "metricSlides": 0, "toolMatches": 21, "documentToolMatches": 0, "frameworkMatches": 14, "arcMatches": 1, "beatMatches": 4, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "af609011-b9d7-4eb8-8bfd-4d656c590a9b", "evidence": "The document follows a clear and structured narrative, similar to the Sequoia Pitch arc, with a focus on problem, solution, market sizing, and clinical trial results.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:42:24.940342+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 9, "name": "Problem", "beatId": "7c3004c9-d14e-4ddd-ac8b-469b44ef6e17", "matchId": "af609011-b9d7-4eb8-8bfd-4d656c590a9b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The document presents the problem of emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events in current cancer therapies.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Solution", "beatId": "27328397-5fb0-424b-acf4-4be675fda1d4", "matchId": "af609011-b9d7-4eb8-8bfd-4d656c590a9b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents Nuvalent's solution, including their innovative approach to cancer therapy and promising clinical trial results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 11, "name": "Market Sizing", "beatId": "7d7613a4-2fa9-47a2-8dd6-439e4bd4ffa2", "matchId": "af609011-b9d7-4eb8-8bfd-4d656c590a9b", "beatType": null, "evidence": "The document presents the market sizing for Nuvalent's therapies, highlighting the significant commercial opportunity.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 12, "name": "Product", "beatId": "b1774785-2429-4d83-9f6f-95b57f9114be", "matchId": "af609011-b9d7-4eb8-8bfd-4d656c590a9b", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "The document presents the product details for Nuvalent's therapies, including NVL-655 and NVL-520.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 9, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48", "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cancer therapies?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:42:25.113036+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 14, "from": 12, "loop": { "name": "40_mece_breakdown", "slug": "40-mece-breakdown", "status": "active", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "canonId": "019dd956-763c-765e-8b68-6ee3ae1ef184", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "2ad14173-59a5-409e-9eff-4f8d228ecb07", "evidence": "The document presents a detailed breakdown of Nuvalent's therapies, including their innovative approach and promising clinical trial results.", "position": 1, "objective": "How do Nuvalent's therapies address the needs of patients with cancer?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:42:25.147606+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Action Titles", "slug": "action-titles", "status": "active", "bestFor": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "canonId": "019dd956-ac70-700b-a608-ba58e78f5dcc", "version": 1, "bodyDocId": "816dad3c-9983-41c1-a86e-978ebd582841", "description": "The McKinsey-bred discipline of writing every slide title as a complete declarative sentence with a verb and an insight, not a topic label. Each title is a sub-claim that ladders up to the deck's governing thought; read in sequence, the titles reconstruct the executive summary.", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "2b9addf5-b2b7-4642-8291-78167b11fecc", "evidence": "The title 'Precisely Targeted Therapies for patients with cancer' and action title 'Nuvalent AT-A-GLANCE' indicate a clear call to action and summary of the company's focus.", "pageRefs": null, "priority": "Core", "whenToUse": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "confidence": 0.8, "extraction": { "at": "2026-07-17 00:41:44.176755+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": "Solves two failure modes at once. (1) The buried claim: action titles place the conclusion on the page before any analysis is read, so a busy reader doesn't reverse-engineer it from the chart. (2) The spineless deck: because each title is a claim, slides have to ladder up to the governing thought; logical gaps become visible as topic-shaped titles in a sequence that no longer reads as a story.", "antipattern": "Topic labels disguised as titles — Volume by quarter, Key findings, Pricing strategy, Margins have been impacted. No verb, or a passive verb with no agent, or a fact (Revenue grew 12%) without the so-what. Also: titles that overreach the chart's evidence, multi-claim X-grew-but-Y-fell welded titles, and mechanical repetition of the same X-drove-Y template across the deck.", "cardinality": null, "narrativePurpose": "Forces the deck to carry its argument in the title bar so a senior reader can extract the recommendation without opening a single slide; converts a binder of topics into a navigable pyramid where every slide is a node defending the apex." }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "57d374d6-febe-4b45-beba-a33dbcb6030d", "evidence": "This slide contains an executive summary of Nuvalent's overview, including key metrics and a brief description of their approach.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:44.136773+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "f9b08a01-e32c-4f66-9cfd-36fd8c059333", "evidence": "AT-A-GLANCE", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:43.331047+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Customer journey map", "slug": "customer-journey-map", "status": "active", "bestFor": null, "canonId": "019de52d-1b26-7499-98c8-1091acc836be", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bbb561ca-8562-4a87-918f-e0dd885b336e", "evidence": "ALK+ NSCLC Patient Journey", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:43.412852+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f4a0d0fd-5263-42d9-bcd4-f373ee1cd933", "evidence": "table/data: Comparison matrix of ALK inhibitors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:41:43.493925+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "1bd1f4f0-0a0e-4f1c-b71a-494b5e34b9b0", "evidence": "chart/bar-grouped: In Vivo Activity Tumor Regression", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:43.574875+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "0a0e66ff-3e92-4f4d-83ac-f24f07421245", "evidence": "chart/dot: In Vitro Activity IC50", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:43.614816+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "320983f5-68a9-4cc4-adc3-18c069e6b3a6", "evidence": "chart/bar-vertical: Brain Penetrance bar chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:43.696957+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7389fb82-ab7d-4f40-ab62-278ccbfb7f4f", "evidence": "chart/waterfall: Waterfall plot comparing tumor response", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:43.778788+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "4f9cb45a-6d75-456d-a693-d77e93a4e735", "evidence": "Swimmer plot of patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:40:02.00666+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Small Multiples", "slug": "small-multiples", "status": "active", "bestFor": null, "canonId": "019dd956-b32d-7586-b368-baa1dd388ed4", "version": 1, "bodyDocId": null, "description": "Repeating similar charts for comparison across categories or time", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "9a635156-505c-4948-8f68-4e05c6bc2114", "evidence": "Swimmer plot of patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:02.105775+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Evidence Matrix", "slug": "evidence-matrix", "status": "active", "bestFor": null, "canonId": "019dd956-7ecc-74c2-b46c-0b9c1f4c73d7", "version": 1, "bodyDocId": null, "description": "Planning visual assets: Claim → Evidence Needed → Data Source → Visual Type", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "f7ee9d7c-1ae7-4f79-a3f8-81d086813e99", "evidence": "Patient 1: EML4-ALK fusion, 5 lines of prior therapy, 50mg QD, complete resolution of brain metastases.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:02.339572+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Storytelling: audience calibration", "slug": "audience", "status": "active", "bestFor": null, "canonId": "019df269-23ea-723a-87c0-af1d78d702d2", "version": 1, "bodyDocId": "019df269-23c5-72ec-8b94-78fc1da7b656", "description": "The same thesis, written for four different audiences, produces four", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "ce83ba91-5dbc-4394-afa4-efc9db43ed05", "evidence": "Patients with TKI-refractory ALK+ NSCLC", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:02.262436+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "af6692a2-33c9-4f5c-bb03-7e01b47ed688", "evidence": "Treatment-Related Adverse Events (TRAEs) in ≥ 5% of patients. All Treated Patients (N = 93)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:40:02.442744+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "957ff253-21f4-41c4-80d4-a496cc5eeef5", "evidence": "The slide contains a list/bullet component with several bullet points.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:52.708324+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "adfc1712-73bb-4668-8f79-817f0f345523", "evidence": "The slide provides an overview of NVL-520 for ROS1+ NSCLC, indicating a specific audience calibration.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:52.829271+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ba99e3a9-952c-463b-a8bb-2c8a1935c812", "evidence": "The slide features a waterfall plot of best percentage change in target lesions by dose cohort.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:53.11307+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "02f5382e-fdd2-44d6-94e1-9b82ebee8ebd", "evidence": "2L+ vs 1L treatment landscape comparison", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:44.112466+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "fcdbe187-7e4a-4c4d-8172-1d511a3bd443", "evidence": "Avoiding EGFR Inhibition chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:44.288551+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "ee122dae-b951-492a-8b06-340fc17196d6", "evidence": "In Vitro Activity, HER2 AND HER2ex20 chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:44.254333+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "5c86240e-7a2f-411c-92f5-62a0c9190056", "evidence": "Nuvalent logo and contact info", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:44.392122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 41, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "e1853ad4-e906-4a3f-8c0a-0d43195a4239", "evidence": "Chronological presentation of milestones from 2021-2023", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:43.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "timeline" }, { "matchId": "31c922bf-da59-4925-bc94-8c56f19b47c5", "evidence": "Chronological progression of goals from 2024 to 2026.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:43.849+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "timeline" }, { "matchId": "648d95d6-7189-4417-ad6a-c44a800bb8cf", "evidence": "Horizontal bars representing development phases over time", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:45.005+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" }, { "matchId": "8f196fb1-d8e5-4143-bf14-9e3d4357bb21", "evidence": "The slide compares two distinct clinical landscapes (ALK+ and ROS1+) side-by-side using identical metrics.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:44.142+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "comparison-frame" }, { "matchId": "361c6a7f-ba77-4c14-bebc-18af94dfe6dd", "evidence": "Uses Osimertinib case study to justify the strategy for ALK/ROS1", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 11:09:45.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "argument-from-analogy" }, { "matchId": "d65aa146-4ffd-4955-b6fe-1593cb696133", "evidence": "The slide maps the clinical progression of patients through lines of therapy (1L, 2L, 3L+).", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:44.544+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "customer-journey-map" }, { "matchId": "a7cefd1a-9d05-4db4-886e-5d928a907b04", "evidence": "The slide compares a new drug against existing market standards across specific criteria.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:44.789+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "frameworkName": "comparison-frame" }, { "matchId": "f809fc64-34a7-4c99-af5c-3847aa0aea20", "evidence": "Visual representation of individual patient treatment duration and response status over time.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:49.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "swimmer-plot" }, { "matchId": "708dfd39-0b83-40fc-9488-29832381b40a", "evidence": "Segments the patient population by treatment line (3L+, 2L, 1L) to define specific value propositions.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:09:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "e8c80601-a1a6-4c21-8d1f-eab8e332b270", "evidence": "Visual timeline showing patient progression through 1L and 2L+ treatment stages.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:47.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "frameworkName": "customer-journey-map" }, { "matchId": "565de599-306c-4a0f-9e04-1f5fa33c72a5", "evidence": "Comparison of drug features across multiple competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:47.042+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "comparison-frame" }, { "matchId": "289efd55-a681-4c29-ba56-d1026993cd27", "evidence": "Side-by-side analysis of 2L+ and 1L treatment settings", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:47.892+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "comparison-frame" }, { "matchId": "5ff9bd1c-94dc-4cbe-9c3e-414cb62de296", "evidence": "Explicitly labeled as 'Target Product Profile' in the slide content.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:48.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "frameworkName": "Target Product Profile" }, { "matchId": "e7eee589-a76a-4c68-a0e6-8d123d9ff956", "evidence": "Chronological progression of goals from 2024 to 2026.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:47.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 40, "frameworkName": "timeline" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "title": "Includes company logo, date, and a molecular visualization.", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/YoLy0YZH-Ew1M5y_a0bI8zjI8uYmL29QdF_S9CX6eH8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81MDYyYjlhOTI1NzYwNjY0OGVhMTQ1YmNjZDY2ZTA0ZC9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 29, "componentCount": 5, "textChars": 93, "nDataPoints": 0, "notes": "Includes company logo, date, and a molecular visualization.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:43.392+00", "seconds": 3.435, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/1", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-1", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.215, "x": 0.758, "y": 0.855 }, "kind": "callout", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f19053fb-3360-468d-841b-0a598acdae1e", "parentComponentId": null }, { "bbox": { "h": 0.82, "w": 0.38, "x": 0.58, "y": 0.14 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4c5da81-11ef-4a0b-873e-e9ff732de526", "parentComponentId": null }, { "bbox": { "h": 0.116, "w": 0.397, "x": 0.088, "y": 0.177 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff68619c-45ce-4f62-958b-0989e6139e6b", "parentComponentId": null }, { "bbox": { "h": 0.032, "w": 0.233, "x": 0.088, "y": 0.648 }, "kind": "paragraph", "text": "January 8, 2024", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9606b1d7-5874-473c-8644-363eaf7c02ba", "parentComponentId": null }, { "bbox": { "h": 0.058, "w": 0.467, "x": 0.088, "y": 0.518 }, "kind": "title", "text": "Nuvalent Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3daa1da0-049d-4ebf-98e5-2c59806c4f57", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/RvnTemiagfzMbfr6ivnEuK4omqhP3NLKKrjBLw3I9vc/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81MDYyYjlhOTI1NzYwNjY0OGVhMTQ1YmNjZDY2ZTA0ZC9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/w8QTyTVW7HOUW_lcaSXBhrNskddoEOHXSEfzgm59IhY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81MDYyYjlhOTI1NzYwNjY0OGVhMTQ1YmNjZDY2ZTA0ZC9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/IsuRG28LsqhzjOJXgmzTjO5jP2oyHMwvmQ2y-TGfZ7Q/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81MDYyYjlhOTI1NzYwNjY0OGVhMTQ1YmNjZDY2ZTA0ZC9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 14, "componentCount": 2, "textChars": 201, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:42.4+00", "seconds": 2.109, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/2", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-2", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.685, "w": 0.886, "x": 0.057, "y": 0.197 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995... [full legal text]", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:42.4+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "764a7cb5-9b62-4a32-a536-82000fe46e52", "parentComponentId": null }, { "bbox": { "h": 0.028, "w": 0.683, "x": 0.057, "y": 0.138 }, "kind": "title", "text": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:42.4+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc477142-a4b1-43cc-80cf-5d93a0277496", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 7, "textChars": 377, "nDataPoints": 2, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:43.61+00", "seconds": 3.293, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/3", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-3", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.4, "x": 0.06, "y": 0.45 }, "kind": "list", "text": "Parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development. Proven discovery capabilities: Third program for HER2+ NSCLC in IND enabling studies & active research pipeline", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3516e1be-eb84-4b35-a7c9-fb4b93c328c0", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.15, "x": 0.55, "y": 0.65 }, "kind": "metric", "text": "Cash runway expected into 2027", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "23780b19-c046-4fd2-aa12-9324ee736ae8", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.15, "x": 0.78, "y": 0.2 }, "kind": "metric", "text": "Hybrid operations with offices in Cambridge, MA", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5841e079-42d9-41fe-b291-99cfbb1acfde", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.15, "x": 0.55, "y": 0.2 }, "kind": "metric", "text": "Growing team (90+ FTEs)", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "686f39d2-d779-4de3-9784-1d11946ae50b", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.15, "x": 0.78, "y": 0.65 }, "kind": "metric", "text": "Nasdaq listed", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ba98fc2c-9195-4160-8ec9-bfae80f8c5b8", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.06, "y": 0.25 }, "kind": "title", "text": "Precisely Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa055b9c-94cc-4c59-9452-acba9c159402", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.1, "y": 0.08 }, "kind": "title", "text": "Nuvalent AT-A-GLANCE", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91b066bf-7132-416b-8ebf-4493940967f1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Action Titles", "slug": "action-titles", "status": "active", "bestFor": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "canonId": "019dd956-ac70-700b-a608-ba58e78f5dcc", "version": 1, "bodyDocId": "816dad3c-9983-41c1-a86e-978ebd582841", "description": "The McKinsey-bred discipline of writing every slide title as a complete declarative sentence with a verb and an insight, not a topic label. Each title is a sub-claim that ladders up to the deck's governing thought; read in sequence, the titles reconstruct the executive summary.", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "2b9addf5-b2b7-4642-8291-78167b11fecc", "evidence": "The title 'Precisely Targeted Therapies for patients with cancer' and action title 'Nuvalent AT-A-GLANCE' indicate a clear call to action and summary of the company's focus.", "pageRefs": null, "priority": "Core", "whenToUse": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "confidence": 0.8, "extraction": { "at": "2026-07-17 00:41:44.176755+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": "Solves two failure modes at once. (1) The buried claim: action titles place the conclusion on the page before any analysis is read, so a busy reader doesn't reverse-engineer it from the chart. (2) The spineless deck: because each title is a claim, slides have to ladder up to the governing thought; logical gaps become visible as topic-shaped titles in a sequence that no longer reads as a story.", "antipattern": "Topic labels disguised as titles — Volume by quarter, Key findings, Pricing strategy, Margins have been impacted. No verb, or a passive verb with no agent, or a fact (Revenue grew 12%) without the so-what. Also: titles that overreach the chart's evidence, multi-claim X-grew-but-Y-fell welded titles, and mechanical repetition of the same X-drove-Y template across the deck.", "cardinality": null, "narrativePurpose": "Forces the deck to carry its argument in the title bar so a senior reader can extract the recommendation without opening a single slide; converts a binder of topics into a navigable pyramid where every slide is a node defending the apex." }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "57d374d6-febe-4b45-beba-a33dbcb6030d", "evidence": "This slide contains an executive summary of Nuvalent's overview, including key metrics and a brief description of their approach.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:44.136773+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "resolution", "title": "The slide uses a 'ribbon' layout to highlight four key pillars of the company's methodology.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 33, "componentCount": 4, "textChars": 298, "nDataPoints": 0, "notes": "The slide uses a 'ribbon' layout to highlight four key pillars of the company's methodology.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:46.107+00", "seconds": 5.74, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/4", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-4", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.735, "w": 0.085, "x": 0.52, "y": 0.116 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.107+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "726c64fc-a809-4631-8565-c949a6bba232", "parentComponentId": null }, { "bbox": { "h": 0.735, "w": 0.315, "x": 0.619, "y": 0.116 }, "kind": "list", "text": "Deep Expertise in Chemistry and Structure-based Drug Design; Design of Target Product Profiles in Collaboration with Physician-Scientists; Aim to Compete in 1st Line with Best-in-Class Profiles; GOAL: Maximize Patient Impact", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.107+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa1c4dd7-2a59-4b6d-a7cf-dbce28de85d2", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.407, "x": 0.117, "y": 0.575 }, "kind": "title", "text": "THE NUVALENT APPROACH", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.107+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b725ea8-9f76-411b-91ce-950417635468", "parentComponentId": null }, { "bbox": { "h": 0.105, "w": 0.455, "x": 0.069, "y": 0.308 }, "kind": "title", "text": "Precisely Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.107+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae728a5b-6fab-42f6-95df-70ff3fbd40bc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "evidence", "title": "The slide uses a chronological structure to demonstrate operational momentum.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 1096, "nDataPoints": 1, "notes": "The slide uses a chronological structure to demonstrate operational momentum.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:43.82+00", "seconds": 3.367, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/5", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-5", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.205 }, "kind": "callout", "text": "Resource-efficient execution and value creation across an expanding portfolio of wholly-owned programs", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "83b165c0-7f65-47b5-b00b-ca96054606ab", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.06, "y": 0.36 }, "kind": "list", "text": "2021: EMERGENCE FROM STEALTH. Disclosed parallel lead programs (ROS1+ and ALK+ NSCLC). Presented preclinical profiles. Nasdaq listed: NUVL.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "448f7330-e386-449d-99d3-c5f6c7589e7f", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.36, "y": 0.36 }, "kind": "list", "text": "2022: FIRST CLINICAL PROOF-OF-CONCEPT. Initiated two global Phase 1/2 studies. Demonstrated clinical proof-of-concept for ROS1 program. Disclosed third novel program (HER2 NSCLC).", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8d7d3ad3-d82e-4f73-b10e-cb354f8cb46c", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.66, "y": 0.36 }, "kind": "list", "text": "2023: SECOND PROOF-OF-CONCEPT & FIRST PIVOTAL STUDY. Demonstrated clinical proof-of-concept for ALK program. Initiated ARROS-1 Phase 2 with registrational intent. Advanced HER2 program towards IND.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa24ae58-5632-43b9-9c60-2a60405d147c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.15, "y": 0.79 }, "kind": "paragraph", "text": "Ended 2023 with approximately $719.9M* in cash, cash equivalents and marketable securities (unaudited), with potential to deliver multiple transformative catalysts within cash runway window into 2027", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5356373c-8eb2-40e4-a16c-9c279bb6dcb9", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.9, "x": 0.05, "y": 0.89 }, "kind": "source-note", "text": "* Preliminary, unaudited estimate only as of the date of this presentation; subject to change following completion of year-end closing procedures; does not present all information necessary for an understanding of financial position as of December 31, 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4adfddb-bb2d-4a0d-904f-c549625bdfd9", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.36, "x": 0.32, "y": 0.1 }, "kind": "title", "text": "Track Record of Success", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a80a73e-9785-46d1-a23f-535fb416582c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e1853ad4-e906-4a3f-8c0a-0d43195a4239", "evidence": "Chronological presentation of milestones from 2021-2023", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:43.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "resolution", "title": "The slide uses a timeline framework to connect high-level goals with specific 2024 milestones.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 4, "textChars": 477, "nDataPoints": 0, "notes": "The slide uses a timeline framework to connect high-level goals with specific 2024 milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:43.849+00", "seconds": 3.267, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/6", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-6", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.45, "x": 0.15, "y": 0.45 }, "kind": "framework", "text": "2024: Execute on global registrational strategies; 2025: First pivotal data; 2026: First approved product", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.849+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05bc4f13-558d-487f-9e63-a6f507f0977d", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.7, "y": 0.2 }, "kind": "list", "text": "Anticipated 2024 Milestones: Progress ARROS-1 Phase 2 with registrational intent; Initiate ALKOVE-1 Phase 2 with registrational intent; Launch 1L ALK strategy; Interim Ph 1/2 data for both ROS1 and ALK programs; Initiate Phase 1 trial for HER2 program", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.849+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f58172f-d31d-412c-a4e0-cae4d8e7dd66", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.2, "y": 0.75 }, "kind": "paragraph", "text": "MISSION: Bringing new, potential best-in-class medicines to patients with cancer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.849+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bce00f56-313e-4e79-8c3f-f5e62a398b65", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "OnTarget 2026: The Path to Patient Impact", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.849+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3450907a-14e5-4cd1-b5e7-98854d1d506d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "31c922bf-da59-4925-bc94-8c56f19b47c5", "evidence": "Chronological progression of goals from 2024 to 2026.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:43.849+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 7, "type": "setup", "title": "The slide uses a split layout with a left panel for advisors/board and a right panel for the leadership team and a footer metric.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 5, "textChars": 182, "nDataPoints": 1, "notes": "The slide uses a split layout with a left panel for advisors/board and a right panel for the leadership team and a footer metric.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:43.392+00", "seconds": 2.648, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/7", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-7", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.55, "x": 0.38, "y": 0.1 }, "kind": "image", "text": "Leadership team photos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "27322db3-3a35-41eb-9349-bec98ad4c3a4", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.05, "y": 0.28 }, "kind": "list", "text": "Board of Directors and Scientific Advisors lists", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58d2ccaf-f553-4144-8c1e-e63859906866", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.55, "x": 0.38, "y": 0.82 }, "kind": "metric", "text": "12 Prior FDA Approvals", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69f11313-87c5-4175-8002-621dec52dc0b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.25, "x": 0.05, "y": 0.18 }, "kind": "paragraph", "text": "Significant experience in drug discovery, development and company building", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f038b12-9c4a-4122-9d76-74df79132e37", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Meet the #NuCrew", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "149e38d7-f5c7-4139-8876-2a289fc1c843", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 8, "type": "resolution", "title": "The slide uses a Gantt-style visualization to represent drug development stages.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 29, "componentCount": 4, "textChars": 230, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization to represent drug development stages.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:45.005+00", "seconds": 4.255, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/8", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-8", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.86, "x": 0.07, "y": 0.35 }, "kind": "chart", "text": "Clinical development pipeline chart", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.005+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c811ced-2034-4cd0-bb8d-0dd72e39036f", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.15, "x": 0.71, "y": 0.045 }, "kind": "list", "text": "Data update at a medical meeting; RP2D & Phase 2 initiation; Phase 1 initiation", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.005+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ecc0e55-d806-40b3-b498-82cd585b8d86", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.1, "y": 0.18 }, "kind": "title", "text": "Advancing a portfolio of potentially best-in-class products, with complementary initial indications in NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.005+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7f6e0c38-9d3b-4067-bc46-34be839a6002", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.23, "y": 0.08 }, "kind": "title", "text": "PIPELINE", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.005+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9fd5b34a-a5fb-4251-97b0-deffda331cb7", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "648d95d6-7189-4417-ad6a-c44a800bb8cf", "evidence": "Horizontal bars representing development phases over time", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:45.005+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 9, "type": "setup", "title": "The slide uses a structured table to highlight gaps in current treatment standards.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 4, "textChars": 420, "nDataPoints": 12, "notes": "The slide uses a structured table to highlight gaps in current treatment standards.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:44.142+00", "seconds": 3.154, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/9", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-9", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.8, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "* Repotrectinib was approved November 2023; ** Not FDA approved, but in NCCN guidelines. 1L, 1st line; 2L, 2nd line; 3L, 3rd line; CNS, central nervous system. Sources (ALK): ... Sources (ROS1): ...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.142+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5981e236-4f0a-4b16-ba07-628eb562b325", "parentComponentId": null }, { "bbox": { "h": 0.52, "w": 0.82, "x": 0.09, "y": 0.31 }, "kind": "table", "text": "Comparison table of ALK+ and ROS1+ NSCLC treatment landscapes", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.142+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa751a3e-8208-48c4-915e-570337181b72", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "title", "text": "Emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events limit utility of approved therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.142+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c284bb79-9c77-4c5f-aeb6-d713a0517bd9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "ALK+ and ROS1+ NSCLC Landscape", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.142+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "59237b1b-3b35-4ca0-bb71-b060547308e4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "8f196fb1-d8e5-4143-bf14-9e3d4357bb21", "evidence": "The slide compares two distinct clinical landscapes (ALK+ and ROS1+) side-by-side using identical metrics.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:44.142+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "comparison-frame" } ], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Problem", "beatId": "7c3004c9-d14e-4ddd-ac8b-469b44ef6e17", "matchId": "af609011-b9d7-4eb8-8bfd-4d656c590a9b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The document presents the problem of emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events in current cancer therapies.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 9, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48", "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cancer therapies?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:42:25.113036+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "resolution", "title": "Uses a 'case study' framework to validate the proposed strategy by drawing a parallel to an existing successful drug (Osimertinib).", "function": "illustrate_case", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 741, "nDataPoints": 8, "notes": "Uses a 'case study' framework to validate the proposed strategy by drawing a parallel to an existing successful drug (Osimertinib).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:45.513+00", "seconds": 4.373, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/10", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-10", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.34, "x": 0.06, "y": 0.543 }, "kind": "callout", "text": "CASE STUDY Osimertinib for EGFR+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e163c75-01bc-4a80-bb6b-ebce719c8a97", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.33, "x": 0.63, "y": 0.543 }, "kind": "chart", "text": "Significant 1L mPFS improvement & Movement up the treatment paradigm", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "93012432-3cd9-47bb-903e-b48a2781a8c6", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.71, "x": 0.145, "y": 0.215 }, "kind": "diagram", "text": "Selective inhibition of the oncogenic driver + Overcoming treatment-emergent resistance mutations + Treating & preventing brain metastases + Avoiding treatment-limiting adverse events", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce473f79-8825-4310-8d80-8a0945b1190a", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.832, "x": 0.084, "y": 0.464 }, "kind": "paragraph", "text": "Comparable resistance mutation rates after 1L TKI: ~50% ALK single mutation & ~40% ROS1 G2032R vs. ~50% EGFR T790M", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "11b81708-b466-4061-9240-9ebacf2e6d26", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.54, "x": 0.06, "y": 0.885 }, "kind": "source-note", "text": "Sources: [1] Dagogo-Jack I. et al., Clin Cancer Res 2019; [2] Gainor J. et al. Cancer Discov. 2016; [4] Gainor J.F. et al., JCO Precision Oncol. 2017; [4] Ohashi K. et al., JCO 2013; [5] Osimertinib FDA package insert.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d69fa9e-1e70-4f29-b524-c05e0a4e9daf", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.586, "x": 0.207, "y": 0.155 }, "kind": "title", "text": "Potential best-in-class ALK & ROS1 TKIs to overcome the combined medical needs of:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf7e99a3-ab33-48ed-acbd-7a119417b43a", "parentComponentId": null }, { "bbox": { "h": 0.038, "w": 0.504, "x": 0.248, "y": 0.065 }, "kind": "title", "text": "Nuvalent ALK+ and ROS1+ NSCLC Strategy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "256f2e57-9ba9-48e0-9d06-1f44d43cfa5a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "361c6a7f-ba77-4c14-bebc-18af94dfe6dd", "evidence": "Uses Osimertinib case study to justify the strategy for ALK/ROS1", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 11:09:45.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "argument-from-analogy" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Solution", "beatId": "27328397-5fb0-424b-acf4-4be675fda1d4", "matchId": "af609011-b9d7-4eb8-8bfd-4d656c590a9b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents Nuvalent's solution, including their innovative approach to cancer therapy and promising clinical trial results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 9, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48", "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cancer therapies?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:42:25.113036+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "resolution", "title": "The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 5, "textChars": 736, "nDataPoints": 3, "notes": "The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:44.458+00", "seconds": 3.162, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/11", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-11", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.5, "x": 0.45, "y": 0.12 }, "kind": "chart", "text": "2022 GLOBAL SALES FOR ALK & ROS1 TKIs", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86d6ce9f-a31d-4afe-ae53-2f47ce980a7c", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.35, "x": 0.05, "y": 0.38 }, "kind": "list", "text": "Potential best-in-class profiles designed with the goal to supplant the current 1L standard of care; Potential near-term registrational opportunity for TKI-pretreated patients; Potential to grow the market through deeper, more durable responses", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "837571e4-dbb4-447d-8203-888c7fe882b6", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.48, "y": 0.78 }, "kind": "source-note", "text": "1L, 1st line; 2L, 2nd line; 3L, 3rd line; B, billion; F, forecasted; M, million; NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. Sources: Cortellis Sales and Forecasts, accessed November 2023; FDA Package Inserts; NCCN Guidelines for NSCLC (version 5.2023).", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f5e22e6-13cc-4bd8-aab4-225a0542d99d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.35, "x": 0.05, "y": 0.25 }, "kind": "title", "text": "Meaningful Commercial Markets with ~$3B Combined WW Sales in 2022", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9b48d98-be8e-416c-aec5-eb366663f053", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "ALK+ & ROS1+ NSCLC Market Opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.458+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cd1c37e5-1552-4b98-8f38-184cea9c1b4c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 11, "name": "Market Sizing", "beatId": "7d7613a4-2fa9-47a2-8dd6-439e4bd4ffa2", "matchId": "af609011-b9d7-4eb8-8bfd-4d656c590a9b", "beatType": null, "evidence": "The document presents the market sizing for Nuvalent's therapies, highlighting the significant commercial opportunity.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 9, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48", "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.", "position": 0, "objective": "What are the consequences of not addressing the limitations of current cancer therapies?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:42:25.113036+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "resolution", "title": "Slide 12 of the deck.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 31, "componentCount": 3, "textChars": 403, "nDataPoints": 0, "notes": "Slide 12 of the deck.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:43.61+00", "seconds": 2.217, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/12", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-12", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.875, "w": 0.286, "x": 0.714, "y": 0 }, "kind": "callout", "text": "AT-A-GLANCE\n\nMechanism of Action:\nALK-selective tyrosine kinase inhibitor\n\nStage of Development:\nGlobal Phase 1\n\nInitial Development Indication:\nALK-positive NSCLC\n\nFDA Designations:\nOrphan Drug Designation", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c0b1b43-a649-4f02-910d-0b2334157863", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.6, "x": 0.08, "y": 0.59 }, "kind": "subtitle", "text": "A brain-penetrant, selective inhibitor of ALK and ALK resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ddc7695d-e972-45db-add9-336e70aa0ec0", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.39, "x": 0.08, "y": 0.395 }, "kind": "title", "text": "NVL-655 for ALK+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:43.61+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a895722e-4624-4d95-80e0-0c17a732f3a4", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "f9b08a01-e32c-4f66-9cfd-36fd8c059333", "evidence": "AT-A-GLANCE", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:43.331047+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Product", "beatId": "b1774785-2429-4d83-9f6f-95b57f9114be", "matchId": "af609011-b9d7-4eb8-8bfd-4d656c590a9b", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "The document presents the product details for Nuvalent's therapies, including NVL-655 and NVL-520.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 12, "loop": { "name": "40_mece_breakdown", "slug": "40-mece-breakdown", "status": "active", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "canonId": "019dd956-763c-765e-8b68-6ee3ae1ef184", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories", "familyLabel": null }, "matchId": "2ad14173-59a5-409e-9eff-4f8d228ecb07", "evidence": "The document presents a detailed breakdown of Nuvalent's therapies, including their innovative approach and promising clinical trial results.", "position": 1, "objective": "How do Nuvalent's therapies address the needs of patients with cancer?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:42:25.147606+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "tension", "title": "The slide uses a timeline-based customer journey framework to map clinical progression against therapeutic limitations.", "function": "frame_problem", "rawType": "customer_journey", "block": null, "metadata": { "slideType": "customer_journey", "slideTypeCanon": { "name": "Customer journey", "slug": "customer_journey", "status": "active", "canonId": "019de52d-0966-70ce-afe3-bc7c98ffc8c9", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 6, "textChars": 298, "nDataPoints": 10, "notes": "The slide uses a timeline-based customer journey framework to map clinical progression against therapeutic limitations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:44.544+00", "seconds": 2.858, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/13", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-13", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.115, "w": 0.695, "x": 0.056, "y": 0.175 }, "kind": "diagram", "text": "1L, 2L, 3L+ progression timeline", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.544+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6495429e-e5ef-4cf5-8c5c-cbc60986e832", "parentComponentId": null }, { "bbox": { "h": 0.88, "w": 0.24, "x": 0.76, "y": 0.12 }, "kind": "image", "text": "Illustrative patient image", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.544+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b951d33-07c5-410a-9428-359abf1a2efa", "parentComponentId": null }, { "bbox": { "h": 0.285, "w": 0.695, "x": 0.056, "y": 0.535 }, "kind": "list", "text": "Key limitations including resistance mutations, brain penetrance, and adverse events", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.544+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0654c8a9-ca3f-4fdc-926b-97503b8cf82e", "parentComponentId": null }, { "bbox": { "h": 0.185, "w": 0.695, "x": 0.056, "y": 0.325 }, "kind": "list", "text": "Standard of care details for 1L, 2L, and 3L+", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.544+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e360f556-174a-4cfc-bae5-185688cdd5a2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.695, "x": 0.056, "y": 0.85 }, "kind": "source-note", "text": "Sources: [1] Kwak E. et al., NEJM 2010... [13] Shiba-Ishii et al., Nature Cancer 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.544+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8c2e7f3-93b1-428f-b66f-19c2e8e2bead", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.485, "x": 0.106, "y": 0.088 }, "kind": "title", "text": "ALK+ NSCLC Patient Journey", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.544+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12e9a5e2-40fc-4a2e-b682-5866dedd134b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Customer journey map", "slug": "customer-journey-map", "status": "active", "bestFor": null, "canonId": "019de52d-1b26-7499-98c8-1091acc836be", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bbb561ca-8562-4a87-918f-e0dd885b336e", "evidence": "ALK+ NSCLC Patient Journey", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:43.412852+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "d65aa146-4ffd-4955-b6fe-1593cb696133", "evidence": "The slide maps the clinical progression of patients through lines of therapy (1L, 2L, 3L+).", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:44.544+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "customer-journey-map" } ], "arcBeats": [], "loops": [ { "to": 14, "from": 12, "loop": { "name": "40_mece_breakdown", "slug": "40-mece-breakdown", "status": "active", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "canonId": "019dd956-763c-765e-8b68-6ee3ae1ef184", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories", "familyLabel": null }, "matchId": "2ad14173-59a5-409e-9eff-4f8d228ecb07", "evidence": "The document presents a detailed breakdown of Nuvalent's therapies, including their innovative approach and promising clinical trial results.", "position": 1, "objective": "How do Nuvalent's therapies address the needs of patients with cancer?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:42:25.147606+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "setup", "title": "The slide uses a matrix-like structure to compare drug generations against clinical outcomes.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 3, "textChars": 382, "nDataPoints": 0, "notes": "The slide uses a matrix-like structure to compare drug generations against clinical outcomes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:44.789+00", "seconds": 2.945, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/14", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-14", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.7, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "Source: Lin J.J. et al., AACR-NCI-EORTC 2023. Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.789+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7ec8373-3714-4136-963a-2ca037d24fa0", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "table", "text": "Comparison matrix of ALK inhibitors (Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib) vs NVL-655 across 5 clinical activity categories.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.789+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05863055-a409-48d6-9fb1-837b7870e18e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "NVL-655: A Rationally Designed ALK-selective, TRK-sparing Inhibitor", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.789+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4b01258-6035-488b-8c32-de3a9954b519", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f4a0d0fd-5263-42d9-bcd4-f373ee1cd933", "evidence": "table/data: Comparison matrix of ALK inhibitors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:41:43.493925+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "a7cefd1a-9d05-4db4-886e-5d928a907b04", "evidence": "The slide compares a new drug against existing market standards across specific criteria.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:44.789+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [ { "to": 14, "from": 12, "loop": { "name": "40_mece_breakdown", "slug": "40-mece-breakdown", "status": "active", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "canonId": "019dd956-763c-765e-8b68-6ee3ae1ef184", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories", "familyLabel": null }, "matchId": "2ad14173-59a5-409e-9eff-4f8d228ecb07", "evidence": "The document presents a detailed breakdown of Nuvalent's therapies, including their innovative approach and promising clinical trial results.", "position": 1, "objective": "How do Nuvalent's therapies address the needs of patients with cancer?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:42:25.147606+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "resolution", "title": "The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 6, "textChars": 395, "nDataPoints": 40, "notes": "The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:45.082+00", "seconds": 3.228, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/15", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-15", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.4, "x": 0.55, "y": 0.35 }, "kind": "chart", "text": "In Vivo Activity Tumor Regression", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.082+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a23a53bc-0778-4efa-ba4e-85ae259f09d4", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.42, "x": 0.06, "y": 0.35 }, "kind": "chart", "text": "In Vitro Activity IC50", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.082+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8787f11b-1021-492e-8e35-e91d5f2d7f7d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "disclaimer", "text": "BID, twice daily; IC50, half-maximal inhibitory concentration; PO, orally; QD, once daily; v, EML4 breakpoint variant. Sources: Lin J.J. et al., AACR-NCI-EORTC 2023...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.082+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69b608a5-a213-4a08-8f62-9464961e7bb5", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.42, "x": 0.06, "y": 0.72 }, "kind": "legend", "text": "Cell lines harboring EML4-ALK fusion, 3-day cell viability assay", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.082+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "82802107-9c94-4095-96e6-e29b741c2f30", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.55, "y": 0.72 }, "kind": "legend", "text": "Xenograft models harboring ALK fusion", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.082+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0f24390-6dff-4e77-9d01-31f6233da61e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preclinical Characterization Demonstrates Desired Target Product Profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.082+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b242d12-538f-483b-815b-fc7edceae8ea", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "1bd1f4f0-0a0e-4f1c-b71a-494b5e34b9b0", "evidence": "chart/bar-grouped: In Vivo Activity Tumor Regression", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:43.574875+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "0a0e66ff-3e92-4f4d-83ac-f24f07421245", "evidence": "chart/dot: In Vitro Activity IC50", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:43.614816+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 16, "type": "resolution", "title": "Includes technical definitions of selectivity index and experimental conditions for Wistar Han rats.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 6, "textChars": 350, "nDataPoints": 2, "notes": "Includes technical definitions of selectivity index and experimental conditions for Wistar Han rats.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:44.757+00", "seconds": 2.846, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/16", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-16", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.2, "x": 0.08, "y": 0.4 }, "kind": "chart", "text": "Brain Penetrance bar chart", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.757+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "042c8f2f-e151-4f70-954b-40f86681d10f", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.2, "x": 0.45, "y": 0.4 }, "kind": "chart", "text": "Selectivity index dot plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.757+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8392e6c8-174c-4fa0-854c-8f93ca6590dc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "disclaimer", "text": "Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.757+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3513f50e-3d88-4806-8411-a0eda319b9d5", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.68, "y": 0.5 }, "kind": "table", "text": "Legend for compound mutants", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.757+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "deace158-c785-4cac-b12e-070ea7df3641", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.05, "y": 0.18 }, "kind": "title", "text": "Brain-Penetrant with the Potential to Avoid TRK-Related CNS Adverse Events", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.757+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80826637-8852-4956-a3f5-ae35cd02cebc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preclinical Characterization Demonstrates Desired Target Product Profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.757+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "71dc7917-d7a6-4a70-8402-2d04444b8748", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "320983f5-68a9-4cc4-adc3-18c069e6b3a6", "evidence": "chart/bar-vertical: Brain Penetrance bar chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:43.696957+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 17, "type": "analysis", "title": "Includes detailed clinical trial enrollment metrics by dose cohort and patient population.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 6, "textChars": 902, "nDataPoints": 36, "notes": "Includes detailed clinical trial enrollment metrics by dose cohort and patient population.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:45.917+00", "seconds": 3.727, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/17", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-17", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.3, "x": 0.06, "y": 0.65 }, "kind": "list", "text": "PHASE 1 OBJECTIVES: Selection of RP2D and, if applicable, MTD (primary); Overall safety and tolerability; PK characterization; Preliminary antitumor activity; Intracranial activity", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.917+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c55ac6b4-a282-4da6-8afe-51c83c1c1d66", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.06, "y": 0.36 }, "kind": "list", "text": "PATIENT POPULATION: Advanced solid tumors harboring ALK fusion or activating mutation; Patients with NSCLC: ≥ 1 prior 2G or 3G ALK TKI; ≤ 2 prior chemotherapies/immunotherapies; Excluded: concurrent oncogenic drivers; Evaluable but non-measurable disease allowed", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.917+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e47383aa-0621-43e2-8b33-ae3ed76142e1", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.3, "x": 0.06, "y": 0.23 }, "kind": "paragraph", "text": "PHASE 1 DOSE-ESCALATION Ongoing at global sites across sites in North America, Europe, Asia and Australia", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.917+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "292c03a2-6d2b-4449-afa8-bd36917d1c58", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.55, "x": 0.39, "y": 0.75 }, "kind": "source-note", "text": "1G, 1st generation ALK TKI... Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.917+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1abde67c-be1e-4323-a21e-3455f7849417", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.55, "x": 0.39, "y": 0.28 }, "kind": "table", "text": "Enrollment table showing NVL-655 dose cohorts (15mg to 200mg) across BOIN Dose-Escalation, Expansion, and NSCLC Response-Evaluable populations.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.917+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "973fdc2e-0dca-44f6-953a-88b350b31609", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "ALKove-1: A Global First-in-Human Phase 1/2 Clinical Trial of NVL-655 in Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.917+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aeb9f908-7306-4c52-9745-2caea2535654", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 18, "type": "analysis", "title": "The slide presents two side-by-side tables detailing patient characteristics and treatment history for the ALKOVE-1 study cohort.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 4, "textChars": 338, "nDataPoints": 32, "notes": "The slide presents two side-by-side tables detailing patient characteristics and treatment history for the ALKOVE-1 study cohort.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:45.077+00", "seconds": 2.778, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/18", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-18", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.45, "x": 0.05, "y": 0.75 }, "kind": "source-note", "text": "Data cut-off: 8 Aug 2023. All data shown as n (%) unless otherwise specified. Abbreviations defined in footer.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "666c473f-5ff5-4b4d-b17a-39e0508b6910", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.45, "x": 0.5, "y": 0.205 }, "kind": "table", "text": "Treatment History table with columns for Treatment History and All Treated (N=93)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4423749-be37-4feb-966f-26b22051035c", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.45, "x": 0.05, "y": 0.205 }, "kind": "table", "text": "Patient Characteristic table with columns for Patient Characteristic and All Treated (N=93)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa34f2e9-c8bb-4959-bb2d-1ac167c22d26", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.5, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Patient Population: Heavily Pretreated ALK+ Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "34c7f9c0-4bda-42d2-bbcc-c0f4bed38b80", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 19, "type": "evidence", "title": "Data cut-off: 8 Aug 2023. Includes detailed breakdown of resistance mutations and prior treatment history.", "function": "analyze_data", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 4, "textChars": 698, "nDataPoints": 64, "notes": "Data cut-off: 8 Aug 2023. Includes detailed breakdown of resistance mutations and prior treatment history.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:45.453+00", "seconds": 2.987, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/19", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-19", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.77 }, "kind": "disclaimer", "text": "Data cut-off: 8 Aug 2023. Response-evaluable patients with ALK+ NSCLC. 1G, 1st generation ALK TKI (crizotinib); 2G, 2nd generation ALK TKI (alectinib, brigatinib, or ceritinib); CNS, central nervous system; NE, not evaluable; ORR, objective response rate; PD, progressive disease, PR, partial response, RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; SD, stable disease, TKI, tyrosine kinase inhibitor.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81979a00-79a3-4afd-81f3-fc94fdb44cd8", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6404d1b5-6f17-4301-8bbd-67848a2b3f59", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "table", "text": "Table showing ORR and best response (PR, SD, PD, NE) across patient cohorts including CNS metastases, resistance mutations, and prior TKI history.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d011b0c-6b8a-4671-9293-0666d8c0ba9f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preliminary Activity: Tumor Response Across Heavily Pretreated Patient Populations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:45.453+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a1324e7c-9b76-4daf-a1db-943d493a18f1", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 20, "type": "evidence", "title": "Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 across different patient cohorts.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 4, "textChars": 322, "nDataPoints": 51, "notes": "Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 across different patient cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:44.992+00", "seconds": 2.312, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/20", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-20", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Waterfall plot comparing tumor response in patients with and without ALK resistance mutations", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ace182f-2544-478a-a5d0-8cf9254d2367", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.1, "x": 0.05, "y": 0.3 }, "kind": "legend", "text": "Dose Level Cohort (mg QD): 200, 150, 100, 50, 25, 15", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "55012a0f-e320-4288-bd93-dc5acd510359", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "paragraph", "text": "Data cut-off: 8 August 2023. Response-evaluable patients with NSCLC.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b32db10-7f9f-431f-b266-d9dbd54343d3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Preliminary Activity: Radiographic Tumor Response in Patients With and Without Known ALK Resistance Mutations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:44.992+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "db547d5c-fa6a-4e08-9358-e6aad027dd3e", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7389fb82-ab7d-4f40-ab62-278ccbfb7f4f", "evidence": "chart/waterfall: Waterfall plot comparing tumor response", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:43.778788+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 21, "type": "evidence", "title": "The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 5, "textChars": 606, "nDataPoints": 4, "notes": "The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:49.403+00", "seconds": 6.641, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/21", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-21", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.75, "x": 0.08, "y": 0.18 }, "kind": "chart", "text": "Swimmer plot of patient treatment duration", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:49.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5906c126-9ce0-40e2-9d24-1164cda1e703", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.45, "x": 0.47, "y": 0.615 }, "kind": "list", "text": "All patients with RECIST 1.1 tumor response remain on treatment without disease progression; 67% (34/51) response-evaluable patients continue treatment; Median (range) duration of treatment: 3.4 (0.3, 12.3) months; Median (range) time to response: 6.1 (5.1, 12.3) weeks", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:49.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad272726-73fa-4837-bb55-8d6dd651e612", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.06, "y": 0.87 }, "kind": "source-note", "text": "Data as of 8 August 2023, for response-evaluable patients with NSCLC. PD, progressive disease; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:49.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e834e1f-89c3-4051-9660-4996d0db70dd", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "NVL-655: ALKOVE-1 PHASE 1", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:49.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c996f430-c02d-4570-9e9d-b4dc2421d809", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.7, "x": 0.06, "y": 0.11 }, "kind": "title", "text": "Time on Treatment: Sustained Duration with Follow-up Ongoing", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:49.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d222b0b1-ef1a-4b65-9ef9-90afaa2b37e8", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "4f9cb45a-6d75-456d-a693-d77e93a4e735", "evidence": "Swimmer plot of patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:40:02.00666+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Small Multiples", "slug": "small-multiples", "status": "active", "bestFor": null, "canonId": "019dd956-b32d-7586-b368-baa1dd388ed4", "version": 1, "bodyDocId": null, "description": "Repeating similar charts for comparison across categories or time", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "9a635156-505c-4948-8f68-4e05c6bc2114", "evidence": "Swimmer plot of patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:02.105775+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "f809fc64-34a7-4c99-af5c-3847aa0aea20", "evidence": "Visual representation of individual patient treatment duration and response status over time.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:49.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "swimmer-plot" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 22, "type": "evidence", "title": "Includes two patient case studies with MRI scans showing tumor reduction.", "function": "show_traction", "rawType": "product_demo", "block": null, "metadata": { "slideType": "product_demo", "slideTypeCanon": { "name": "Product demo", "slug": "product_demo", "status": "active", "canonId": "019de52d-0f06-7288-84f2-7568c1020fce", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 6, "textChars": 625, "nDataPoints": 4, "notes": "Includes two patient case studies with MRI scans showing tumor reduction.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:50.157+00", "seconds": 7.352, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/22", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-22", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.7, "x": 0.05, "y": 0.87 }, "kind": "disclaimer", "text": "Data as of 8 August 2023. CNS, central nervous system; CR, complete response; NSCLC, Non-small cell lung cancer; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:50.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6e905eb-c89d-4723-8a2a-37fca86f5543", "parentComponentId": null }, { "bbox": { "h": 0.28, "w": 0.14, "x": 0.72, "y": 0.35 }, "kind": "image", "text": "MRI scans for Intracranial Partial Response case", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:50.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cba91516-dbbd-4ef1-95cc-0507577c28b9", "parentComponentId": null }, { "bbox": { "h": 0.28, "w": 0.14, "x": 0.33, "y": 0.35 }, "kind": "image", "text": "MRI scans for Intracranial Complete Response case", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:50.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe3934f4-8f39-489c-bf92-29dbdc126dc5", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.05, "y": 0.33 }, "kind": "list", "text": "Patient 1: EML4-ALK fusion, 5 lines of prior therapy, 50mg QD, complete resolution of brain metastases.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:50.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ab0f21f-1d13-46f4-b7ea-af1839368b77", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.53, "y": 0.33 }, "kind": "list", "text": "Patient 2: EML4-ALK fusion with L1196Q mutation, 3 lines of prior therapy, 150mg QD, partial response.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:50.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98e0d4df-b335-424d-8956-ce4274df457c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "CNS Activity: NVL-655 Induced Intracranial Responses in Patients with TKI-Refractory ALK+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:50.157+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9052f4b-a28a-44d5-ad07-490f1ab575b7", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Evidence Matrix", "slug": "evidence-matrix", "status": "active", "bestFor": null, "canonId": "019dd956-7ecc-74c2-b46c-0b9c1f4c73d7", "version": 1, "bodyDocId": null, "description": "Planning visual assets: Claim → Evidence Needed → Data Source → Visual Type", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "f7ee9d7c-1ae7-4f79-a3f8-81d086813e99", "evidence": "Patient 1: EML4-ALK fusion, 5 lines of prior therapy, 50mg QD, complete resolution of brain metastases.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:02.339572+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Storytelling: audience calibration", "slug": "audience", "status": "active", "bestFor": null, "canonId": "019df269-23ea-723a-87c0-af1d78d702d2", "version": 1, "bodyDocId": "019df269-23c5-72ec-8b94-78fc1da7b656", "description": "The same thesis, written for four different audiences, produces four", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "ce83ba91-5dbc-4394-afa4-efc9db43ed05", "evidence": "Patients with TKI-refractory ALK+ NSCLC", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:40:02.262436+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 23, "type": "analysis", "title": "Data cut-off: 8 Aug 2023. N=93 patients.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 4, "textChars": 721, "nDataPoints": 32, "notes": "Data cut-off: 8 Aug 2023. N=93 patients.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:46.446+00", "seconds": 3.523, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/23", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-23", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.8 }, "kind": "disclaimer", "text": "Data cut-off: 8 Aug 2023. Abbreviations: ALT, AST, CPK, DLT, TRAE. Footnotes regarding specific patient outcomes and source.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.446+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d314634-6914-4bcc-9686-bae112066741", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.35, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "MTD has not been identified; 1 DLT: transient asymptomatic Grade 4 CPK increase. Infrequent TRAEs requiring dose modification: 2% discontinued, 5% dose-reduced. Preliminary overall safety profile consistent with avoiding TRK-related neurotoxicities.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.446+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad9fb98f-18d2-4124-b59d-5186f62b8a92", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.55, "x": 0.42, "y": 0.25 }, "kind": "table", "text": "Treatment-Related Adverse Events (TRAEs) in ≥ 5% of patients. All Treated Patients (N = 93). Columns: Grade 1, Grade 2, Grade ≥3, Any Grade. Rows: Any TRAE, ALT increased, AST increased, Nausea, Dysgeusia, Constipation, Fatigue, Peripheral edema.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.446+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da0549e1-1f98-4597-9b38-68b7a9717906", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Preliminary Safety Profile: Favorable and Consistent with ALK-Selective, TRK-Sparing Design of NVL-655", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.446+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1773229e-5c39-428e-bab9-f44f0e8d68de", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "af6692a2-33c9-4f5c-bb03-7e01b47ed688", "evidence": "Treatment-Related Adverse Events (TRAEs) in ≥ 5% of patients. All Treated Patients (N = 93)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:40:02.442744+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 24, "type": "resolution", "title": "The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 6, "textChars": 1093, "nDataPoints": 6, "notes": "The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:46.502+00", "seconds": 3.348, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/24", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-24", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.9, "x": 0.058, "y": 0.85 }, "kind": "disclaimer", "text": "Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted. Sources: Cortellis Sales and Forecasts, accessed November 2023; Ou and Zhu Lung Cancer 2019; Kris et. al. JAMA 2014; Shaw and Engelman J Clin Onc 2013; Noé et. al. J Thor Onc 2019; Peters et. al. NEJM 2017; Shaw et. al. Lancet Onc 2017; Dagogo-Jack et. al. Clin Cancer Res 2019; Lin J.J. et al., AACR-NCI-EORTC 2023; FDA Package Inserts for alectinib and lorlatinib; Camidge D.R., J Thorac Onc. 2021.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6136f0ff-a1c5-4b34-b506-ced5f36739e4", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.67, "y": 0.27 }, "kind": "list", "text": "1L: Current SOC: Alectinib; ALK: ~3-5% of NSCLC; ~30-40% CNS disease. Opportunity to supplant standard of care with a differentiated profile.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2bfc583c-4aad-4e43-aae6-03a3c802b98b", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.36, "y": 0.27 }, "kind": "list", "text": "2L: Current SOC: Lorlatinib; ~50% single mutations; >60% CNS disease. Opportunity to differentiate with deep, durable responses and TRK-sparing profile.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5417619c-d581-4f09-add6-57dfb8094fb6", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.05, "y": 0.27 }, "kind": "list", "text": "3L+: No clear standard of care; ~25-50% compound mutations; >60% CNS disease. Demonstrated activity where current therapies failed.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3ead653-f675-4c42-a43a-8c29f0addee7", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.75, "x": 0.058, "y": 0.19 }, "kind": "title", "text": "Opportunity to both move up the treatment paradigm & grow the market with deep, durable responses", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "29358e10-a462-45e8-9af1-df71081494eb", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.42, "x": 0.058, "y": 0.118 }, "kind": "title", "text": "Potential Best-in-class Profile for ALK+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "34927d82-5895-4082-825f-fe1a86da6cc1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "957ff253-21f4-41c4-80d4-a496cc5eeef5", "evidence": "The slide contains a list/bullet component with several bullet points.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:52.708324+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "708dfd39-0b83-40fc-9488-29832381b40a", "evidence": "Segments the patient population by treatment line (3L+, 2L, 1L) to define specific value propositions.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:09:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 25, "type": "resolution", "title": "The slide outlines a multi-cohort study design with specific patient populations and trial objectives.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 5, "textChars": 681, "nDataPoints": 0, "notes": "The slide outlines a multi-cohort study design with specific patient populations and trial objectives.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:46.369+00", "seconds": 3.08, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/25", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-25", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.6, "x": 0.05, "y": 0.18 }, "kind": "callout", "text": "Multi-pronged development strategy supports goal of moving up the treatment paradigm", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c13172f4-8072-4b5d-a44f-f434be67e1dd", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.58, "x": 0.38, "y": 0.72 }, "kind": "list", "text": "Primary: ORR by blinded, independent central review; Secondary: Additional efficacy measures (DOR, TTR, CBR, PFS, OS), intracranial activity, overall safety and tolerability, confirmation of PK profile", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cfd3ed9a-d496-412f-9d80-4587780d75a0", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.9, "x": 0.05, "y": 0.92 }, "kind": "paragraph", "text": "1L, 1st line; 2L, 2nd line; 3L, 3rd Line; CBR, clinical benefit rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival; PK, pharmacokinetics; TKI, tyrosine kinase inhibitor; TTR, time to response.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13d8b5a1-4141-4d52-b757-f6b4d4f88b2d", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.58, "x": 0.38, "y": 0.33 }, "kind": "table", "text": "ALKOVE-1 Cohort 2a, 2b, 2c, 2d details including tumor type, prior TKI, prior chemo, and intent.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d7972908-c24d-43be-b28c-e2dc4506a1c7", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Planned Clinical Development for ALK+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5861afed-2cbf-412f-977f-b95f2b43c628", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 26, "type": "setup", "title": "The slide uses a sidebar 'AT A GLANCE' to summarize key drug development parameters.", "function": "establish_context", "rawType": "context", "block": null, "metadata": { "slideType": "context", "slideTypeCanon": { "name": "Context (pitchdeck)", "slug": "context", "status": "active", "canonId": "019de52d-1094-779e-9590-e4603e6a191c", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 3, "textChars": 431, "nDataPoints": 0, "notes": "The slide uses a sidebar 'AT A GLANCE' to summarize key drug development parameters.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:46.756+00", "seconds": 2.998, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/26", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-26", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.88, "w": 0.285, "x": 0.715, "y": 0 }, "kind": "callout", "text": "AT A GLANCE\nMechanism of Action: ROS1-selective tyrosine kinase inhibitor\nStage of Development: Global Phase 2 with registrational intent\nInitial Development Indication: ROS1-positive NSCLC\nFDA Designations: Orphan Drug Designation", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.756+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c2186aa-0f04-40b1-805b-7218d33e66af", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.65, "x": 0.08, "y": 0.59 }, "kind": "paragraph", "text": "A brain-penetrant, selective inhibitor of ROS1 and ROS1 resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.756+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72282bc5-0ed9-4b52-a04d-193ed0b41981", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.42, "x": 0.08, "y": 0.395 }, "kind": "title", "text": "NVL-520 for ROS1+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.756+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "97e3d654-8945-454f-a44f-cdcb3e99ebef", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "adfc1712-73bb-4668-8f79-817f0f345523", "evidence": "The slide provides an overview of NVL-520 for ROS1+ NSCLC, indicating a specific audience calibration.", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:52.829271+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "setup", "title": "The slide uses a timeline-based framework to contrast current treatment options with clinical unmet needs.", "function": "present_framework", "rawType": "customer_journey", "block": null, "metadata": { "slideType": "customer_journey", "slideTypeCanon": { "name": "Customer journey", "slug": "customer_journey", "status": "active", "canonId": "019de52d-0966-70ce-afe3-bc7c98ffc8c9", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 6, "textChars": 423, "nDataPoints": 8, "notes": "The slide uses a timeline-based framework to contrast current treatment options with clinical unmet needs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.343+00", "seconds": 3.427, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/27", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-27", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.5, "x": 0.1, "y": 0.17 }, "kind": "callout", "text": "~1 – 3% of NSCLC | Majority are advanced/metastatic at diagnosis", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1cfdfa7-27a5-423a-b3e3-cec1c089caf7", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.06, "y": 0.24 }, "kind": "framework", "text": "1L and 2L+ treatment timeline", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c3eee9cf-5592-471c-aae1-f6d20e55c4d6", "parentComponentId": null }, { "bbox": { "h": 1, "w": 0.25, "x": 0.75, "y": 0 }, "kind": "image", "text": "Illustrative patient image", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5037af4-9fc9-41ea-b1cd-026e76d4ab85", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.68, "x": 0.06, "y": 0.85 }, "kind": "source-note", "text": "Sources: [1] Drilon A. et al., Nat Rev Clin Oncol. 2021. [2] Jordan E.J. et al., Cancer Discovery 2017. [3] Parikh D.A. et al., JCO Oncol Pract. 2020. [4] Cortellis Sales and Forecasts... [11] Shaw, A. et al. NEJM 2020.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f77adad2-6511-43e1-a232-7bd52106f249", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.68, "x": 0.06, "y": 0.33 }, "kind": "table", "text": "Standard of Care and Key Limitations for 1L and 2L+ stages", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5c96b6c-e8e4-40f6-b05b-0c813888bf82", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.06, "y": 0.09 }, "kind": "title", "text": "ROS1+ NSCLC Patient Journey", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49c9c16c-cec1-46a7-87c7-73dad8b757e1", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e8c80601-a1a6-4c21-8d1f-eab8e332b270", "evidence": "Visual timeline showing patient progression through 1L and 2L+ treatment stages.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:47.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "frameworkName": "customer-journey-map" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "setup", "title": "The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 504, "nDataPoints": 0, "notes": "The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.042+00", "seconds": 3.12, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/28", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-28", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.35, "x": 0.625, "y": 0.21 }, "kind": "callout", "text": "NVL-520 Preliminary Phase 1 Conclusions (Drilon A. et al., EORTC-NCI-AACR 2022)", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.042+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab9eabd2-3e5d-47a4-a657-d0402f708042", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "Source: Drilon A. et al., EORTC-NCI-AACR 2022. Head-to-head clinical studies comparing NVL-520 with currently approved or investigational therapies have not been conducted.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.042+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "facec28b-90d3-4fa4-b361-46eb996567ba", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "table", "text": "Comparison matrix of ROS1 inhibitors (Crizotinib, Entrectinib, Lorlatinib, Repotrectinib, Taletrectinib) vs NVL-520 across ROS1 activity, Mutant activity, CNS activity, and TRK sparing.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.042+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af815192-5216-4b87-a45d-e362d81d8067", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "NVL-520: A Rationally Designed ROS1-selective, TRK-sparing Inhibitor", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.042+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ddc2c36-d8f2-4ab9-847a-4cd8fbae21c2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "565de599-306c-4a0f-9e04-1f5fa33c72a5", "evidence": "Comparison of drug features across multiple competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:47.042+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 29, "type": "resolution", "title": "The slide uses three distinct chart types to demonstrate competitive advantages in potency, PK, and selectivity.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 5, "textChars": 315, "nDataPoints": 18, "notes": "The slide uses three distinct chart types to demonstrate competitive advantages in potency, PK, and selectivity.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:46.933+00", "seconds": 2.969, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/29", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-29", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.35, "x": 0.58, "y": 0.22 }, "kind": "chart", "text": "Avoiding TRK Inhibition", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.933+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6fe6031-b53c-4484-81e8-4ea23b9df415", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.15, "x": 0.38, "y": 0.22 }, "kind": "chart", "text": "Brain Penetrance", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.933+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1830ab2c-0106-43c5-8087-7049a74f8ed4", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.05, "y": 0.22 }, "kind": "chart", "text": "In Vitro Activity, ROS1 Wild-type & Mutant", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.933+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e29ee91-9823-4a35-944e-83e8ee198a03", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.85 }, "kind": "disclaimer", "text": "Head-to-head clinical studies comparing NVL-520 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.933+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "26931fb2-0462-4ea7-abaa-defa2471be91", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preclinical Characterization Demonstrates Desired Target Product Profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:46.933+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9b70d7a-fd8a-4150-980f-d3838fb88515", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 30, "type": "evidence", "title": "The slide presents a clinical trial snapshot including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 6, "textChars": 977, "nDataPoints": 24, "notes": "The slide presents a clinical trial snapshot including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:48.034+00", "seconds": 4.022, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/30", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-30", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.55, "x": 0.4, "y": 0.7 }, "kind": "disclaimer", "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; mg, milligram; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; QD, once daily; RP2D, recommended phase 2 dose; ROS1+, ROS1-positive; TKI, tyrosine kinase inhibitor.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.034+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35cefdcb-a9d4-4da7-94b0-b512ae5dec92", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.35, "x": 0.05, "y": 0.65 }, "kind": "list", "text": "OBJECTIVES: Selection of RP2D and MTD; Overall safety and tolerability; PK characterization; Preliminary antitumor activity; Intracranial activity.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.034+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2a3b5308-9d8a-4cad-9b8c-6fb2767b0670", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.05, "y": 0.35 }, "kind": "list", "text": "PATIENT POPULATION: Advanced solid tumors harboring ROS1 fusions; ≥ 1 prior ROS1 TKI; No limit to prior chemo/immuno; Excluded concurrent drivers; Evaluable but non-measurable allowed.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.034+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb212d83-35c1-43df-b95c-b3bbb0161881", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.05, "y": 0.22 }, "kind": "paragraph", "text": "PHASE 1 DOSE-ESCALATION. Phase 1 enrollment completed August 2023: Updated data to be presented at a medical meeting in 2024", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.034+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7af0ebae-a3b3-4976-99b1-29f71256e941", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.55, "x": 0.4, "y": 0.3 }, "kind": "table", "text": "NVL-520 Dose Cohorts enrollment table showing N=35 total treated population across 25mg, 50mg, 75mg, 100mg, 125mg cohorts.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.034+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa2571b0-2ecf-44ef-a677-1b710bd07c46", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "ARROS-1: A Global First-in-Human Phase 1/2 Clinical Trial of NVL-520 in Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.034+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d7e9679-be65-4d44-a873-a37772b02106", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 31, "type": "analysis", "title": "The slide presents two side-by-side tables detailing patient characteristics and treatment history for a clinical trial cohort.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 4, "textChars": 756, "nDataPoints": 30, "notes": "The slide presents two side-by-side tables detailing patient characteristics and treatment history for a clinical trial cohort.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.266+00", "seconds": 3.053, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/31", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-31", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.4, "x": 0.07, "y": 0.78 }, "kind": "disclaimer", "text": "Data as of 13 Sep 2022, for patients treated by 01 Sep 2022. All data shown as n (%) unless otherwise specified. CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; TKI, tyrosine kinase inhibitor. a Includes patients with untreated CNS lesions. b Categories are not mutually exclusive. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.266+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da58c368-52b8-48a6-af2d-73a8a39fcbb1", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.48, "y": 0.22 }, "kind": "table", "text": "Treatment History table showing prior lines of therapy, prior treatments, and specific ROS1 TKIs received.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.266+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3a0fff7e-f1ff-42b3-bdbd-2c83c1dc276b", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.4, "x": 0.07, "y": 0.22 }, "kind": "table", "text": "Patient Characteristic table showing age, gender, tumor type, ECOG PS, smoking status, and CNS metastasis history.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.266+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "728469d3-1882-4e7d-9f1f-f55a74389361", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Patient Population: Heavily Pretreated ROS1+ Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.266+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e7d368c-f55c-4a50-a61a-a47dad262593", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 32, "type": "evidence", "title": "Includes a summary table of best responses and a waterfall plot showing percentage change in target lesions by dose cohort.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 473, "nDataPoints": 45, "notes": "Includes a summary table of best responses and a waterfall plot showing percentage change in target lesions by dose cohort.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.282+00", "seconds": 2.997, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/32", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-32", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.55, "x": 0.384, "y": 0.49 }, "kind": "chart", "text": "Waterfall plot of best percentage change in target lesions by dose cohort.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.282+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "613bb9b6-9db5-4bf5-aee4-2a4aa6b8537f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.06, "y": 0.23 }, "kind": "list", "text": "NVL-520 induced tumor response across heavily pretreated patient populations. Radiographic tumor regression observed across all NVL-520 dose levels.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.282+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c19b67b8-46c4-4b66-801a-a2e333ea81d7", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.3, "x": 0.06, "y": 0.57 }, "kind": "paragraph", "text": "Data as of 13 Sep 2022, for response-evaluable patients with NSCLC treated by 01 Sep 2022.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.282+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb4cbcb5-d3d8-4493-be33-443fdcd769bc", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.55, "x": 0.384, "y": 0.072 }, "kind": "table", "text": "ORR across all dose levels (RECIST 1.1) for various patient subgroups (All NSCLC, ROS1 G2032R, CNS Metastases, etc.)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.282+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "200f24b0-5959-4a30-a885-28fa722141aa", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.32, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "NVL-520: ARROS-1 Phase 1 Preliminary Activity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.282+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "108afb5b-969f-48ca-ba40-fe8e9826209c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "ba99e3a9-952c-463b-a8bb-2c8a1935c812", "evidence": "The slide features a waterfall plot of best percentage change in target lesions by dose cohort.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:53.11307+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 33, "type": "evidence", "title": "Includes clinical trial data from ARROS-1 Phase 1 study.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 8, "textChars": 684, "nDataPoints": 8, "notes": "Includes clinical trial data from ARROS-1 Phase 1 study.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.987+00", "seconds": 3.634, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/33", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-33", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.15, "x": 0.6, "y": 0.15 }, "kind": "chart", "text": "Reduction in ROS1 G2032R Allele", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "471cac44-733e-4960-9a30-d3252179c7bf", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.2, "x": 0.38, "y": 0.15 }, "kind": "chart", "text": "Reduction in Tumor Burden in Cancers with ROS1 G2032R", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3e10637d-2e2f-4fc5-a022-735d0f493d91", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.2, "x": 0.78, "y": 0.52 }, "kind": "disclaimer", "text": "Data as of 13 Sep 2022, for patients treated by 01 Sep 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b8870171-0fcb-4f23-9f31-ed3a37fef761", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.38, "y": 0.55 }, "kind": "image", "text": "NVL-520 Induced Responses in Intracranial Lesions", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "61f884d3-4c97-4f72-a8ab-c9d0cbea2cc0", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.05, "y": 0.23 }, "kind": "list", "text": "ROS1 Resistance Mutations: Subgroup with known ROS1 G2032R resistance mutation: ORR: 78% (7/9); 100% (9/9) with tumor shrinkage. One patient with ROS1 D2033N with ongoing PR (-40%) pending confirmation.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7577748-86b7-457e-a807-31313229b0e7", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.05, "y": 0.53 }, "kind": "list", "text": "CNS Activity: Intracranial PR in 3/3 patients with measurable (>10 mm) CNS metastases. ORR of 73% (8/11) in response-evaluable patients with history of CNS metastases. No CNS progression observed in any of the 35 treated patients.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5410dd8-445a-4829-81de-a5a772dfd758", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74b5c3a9-0343-43a6-a5ff-2686078900a2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "Key Subgroups", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5ab5a7ad-2901-47ce-9bad-7d886a1a2612", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 34, "type": "analysis", "title": "Data as of 13 Sep 2022. N=35 patients.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 4, "textChars": 684, "nDataPoints": 24, "notes": "Data as of 13 Sep 2022. N=35 patients.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.961+00", "seconds": 3.495, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/34", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-34", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.32, "x": 0.08, "y": 0.34 }, "kind": "list", "text": "No DLTs; No treatment-related SAEs; No AEs leading to dose reduction or discontinuation; No treatment-related dizziness", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "402c6d4e-f7f3-4e2e-9f43-80abb07d0fe9", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.72, "x": 0.058, "y": 0.85 }, "kind": "source-note", "text": "Data as of 13 Sep 2022, for patients treated by 01 Sep 2022. AE, adverse event; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; DLT, dose-limiting toxicity; SAE, serious adverse event. a Including oedema and oedema peripheral. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4882a9f5-808f-4362-86f5-541ef71115de", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.52, "x": 0.398, "y": 0.275 }, "kind": "table", "text": "Treatment-Related Adverse Events (TRAEs) in >1 Patient. All Treated Patients (N = 35). Table rows: Fatigue, Nausea, ALT increased, AST increased, Oedema, Myalgia.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "71932d27-2fe6-4e7f-ad8b-8cde3e121384", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.84, "x": 0.058, "y": 0.113 }, "kind": "title", "text": "Preliminary Safety Profile: Favorable and Consistent with the Highly ROS1-Selective, TRK-Sparing Design of NVL-520", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e779900-817c-4c01-a2ee-15a494e49330", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 35, "type": "evidence", "title": "The chart shows pharmacokinetic curves for four different dose levels against four target efficacy thresholds.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 344, "nDataPoints": 4, "notes": "The chart shows pharmacokinetic curves for four different dose levels against four target efficacy thresholds.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.679+00", "seconds": 3.126, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/35", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-35", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.4, "x": 0.52, "y": 0.3 }, "kind": "chart", "text": "Preliminary pharmacokinetic profile", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "adb26e6e-91a7-4a31-896a-02b37a5b95a6", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.06, "y": 0.85 }, "kind": "disclaimer", "text": "Data as of 13 Sep 2022... Source: Data on file; Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f15de30a-2fe7-4040-b14e-d4911f6e6b46", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.06, "y": 0.03 }, "kind": "list", "text": "MTD was not reached; No clinically significant exposure-response relationships; Wide therapeutic window; 100 mg daily maintained steady state levels above thresholds.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "53beaf2d-2a94-4005-aeb0-0c9ffb42b3ee", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.06, "y": 0.11 }, "kind": "title", "text": "RP2D of 100mg QD Met All Desired Clinical Characteristics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca1275e5-8772-4de2-bc6e-101266e78be0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 36, "type": "setup", "title": "The slide uses a comparative framework to highlight unmet needs in 2L+ and the potential for market leadership in 1L.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 4, "textChars": 404, "nDataPoints": 8, "notes": "The slide uses a comparative framework to highlight unmet needs in 2L+ and the potential for market leadership in 1L.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.892+00", "seconds": 2.961, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/36", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-36", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.58, "w": 0.688, "x": 0.156, "y": 0.268 }, "kind": "list", "text": "2L+ vs 1L treatment landscape comparison", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Comparison list", "slug": "comparison", "status": "active", "canonId": "019de52c-fce7-733e-99d3-030a104727bf", "version": 1, "description": null }, "framework": null }, "subkind": "comparison", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.892+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0f528c4-4d09-4d2f-aa05-67ef05c7b17e", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.82, "x": 0.058, "y": 0.89 }, "kind": "source-note", "text": "Sources: Cortellis Sales and Forecasts, accessed November 2023; Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018; Drilon A., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.892+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22184b44-383d-4861-8dd7-4569084b1b30", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.65, "x": 0.058, "y": 0.19 }, "kind": "title", "text": "Opportunity to both move up the treatment paradigm & grow the market with deep, durable responses", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.892+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b0d85249-e403-48a0-8c38-ad5d8d684964", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.42, "x": 0.058, "y": 0.118 }, "kind": "title", "text": "Potential Best-in-class Profile for ROS1+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.892+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6cee72be-f2a6-49bc-be99-1ac51abd44d6", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "02f5382e-fdd2-44d6-94e1-9b82ebee8ebd", "evidence": "2L+ vs 1L treatment landscape comparison", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:44.112466+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "289efd55-a681-4c29-ba56-d1026993cd27", "evidence": "Side-by-side analysis of 2L+ and 1L treatment settings", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:09:47.892+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 37, "type": "resolution", "title": "The slide outlines a multi-cohort study design for NVL-520, distinguishing between registrational cohorts and an exploratory cohort.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 75, "componentCount": 6, "textChars": 859, "nDataPoints": 5, "notes": "The slide outlines a multi-cohort study design for NVL-520, distinguishing between registrational cohorts and an exploratory cohort.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:48.335+00", "seconds": 3.297, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/37", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-37", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.3, "x": 0.06, "y": 0.48 }, "kind": "list", "text": "Enrollment planned across North America, Europe, Asia and Australia. All patients receive NVL-520 at 100 mg QD. Primary Objective: ORR by blinded, independent central review. Secondary Objectives: Additional efficacy measures.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f1f2ddd-7cd2-4c0d-8d24-6f25e0a7dc5d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.06, "y": 0.3 }, "kind": "paragraph", "text": "ARROS-1 for TKI-naïve and TKI pre-treated ROS1+ NSCLC (N ≈ 225). Ongoing global open-label, multi-cohort Phase 2 with registrational intent.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "736bcd72-895b-440b-8351-bb8a81e83dc6", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.55, "x": 0.38, "y": 0.82 }, "kind": "source-note", "text": "1L, 1st line; 2L, 2nd line; CBR, clinical benefit rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival; PK, pharmacokinetics; PRO, patient reported outcomes; QD, once daily; TKI, tyrosine kinase inhibitor; TTR, time to response.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cfe5f8c0-eba0-4695-b460-ee934e80e0b5", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.55, "x": 0.38, "y": 0.35 }, "kind": "table", "text": "ARROS-1 Phase 2 Cohort breakdown by tumor type, treatment status, and prior therapy.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54c93c81-7d5f-4541-b3e4-c6c91bc7fa94", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.05, "y": 0.18 }, "kind": "title", "text": "Ongoing ARROS-1 Phase 2 supports goal of moving up the treatment paradigm", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5798d0bb-b443-4cf8-a991-a040782e2a66", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.45, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Clinical Development Strategy for ROS1+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.335+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b98f340-f876-4e2a-a9b9-8b4dd030db5e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 38, "type": "setup", "title": "The slide uses a 'Target Product Profile' framework to summarize the drug's key characteristics.", "function": "present_solution", "rawType": "product_demo", "block": null, "metadata": { "slideType": "product_demo", "slideTypeCanon": { "name": "Product demo", "slug": "product_demo", "status": "active", "canonId": "019de52d-0f06-7288-84f2-7568c1020fce", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 5, "textChars": 577, "nDataPoints": 1, "notes": "The slide uses a 'Target Product Profile' framework to summarize the drug's key characteristics.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:48.051+00", "seconds": 2.834, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/38", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-38", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.35, "x": 0.58, "y": 0.4 }, "kind": "list", "text": "Target Product Profile:\nActive against HER2 and HER2ex20\nEGFR sparing: Related adverse events include skin rash and diarrhea\nBrain penetrant: ~19% of patients with HER2-positive NSCLC present with brain metastases", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4ae23085-8fe5-45a6-9c8b-64f946f33601", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.58, "y": 0.12 }, "kind": "list", "text": "Mechanism of Action: HER2-selective tyrosine kinase inhibitor\nStage of Development: IND-enabling studies; Phase 1 initiation planned in 2024\nInitial Development Indication: HER2-positive NSCLC", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "814a7102-6ef2-472f-b018-bf272272d8e3", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.08, "y": 0.58 }, "kind": "paragraph", "text": "A brain-penetrant, HER2-selective inhibitor with activity against HER2 mutations and the potential to minimize EGFR-related adverse events", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6fcbe5f6-b98b-43f5-81f2-60c1299a7e32", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.65, "y": 0.05 }, "kind": "title", "text": "AT A GLANCE", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "38d9fead-ed8f-40f6-9e6b-72ff76b5205b", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.08, "y": 0.38 }, "kind": "title", "text": "NVL-330 for HER2+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:48.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5fb1791a-f873-4141-ab63-2b673529b4f3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "5ff9bd1c-94dc-4cbe-9c3e-414cb62de296", "evidence": "Explicitly labeled as 'Target Product Profile' in the slide content.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:48.051+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "frameworkName": "Target Product Profile" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 39, "type": "resolution", "title": "Includes three distinct preclinical assay results: In Vitro Activity, Selectivity Index, and Brain Penetrance.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 5, "textChars": 446, "nDataPoints": 15, "notes": "Includes three distinct preclinical assay results: In Vitro Activity, Selectivity Index, and Brain Penetrance.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.945+00", "seconds": 2.712, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/39", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-39", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.2, "x": 0.73, "y": 0.35 }, "kind": "chart", "text": "Brain Penetrance", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a2953650-e604-401c-8f8a-1e2911d8dbf7", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.38, "y": 0.35 }, "kind": "chart", "text": "Avoiding EGFR Inhibition", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c283803d-a525-4edf-80c8-4dc59012a003", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.3, "x": 0.06, "y": 0.35 }, "kind": "chart", "text": "In Vitro Activity, HER2 AND HER2ex20", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac87cb21-c7cd-4b69-91d0-17b9c3253016", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.87 }, "kind": "source-note", "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-330. Above data from preclinical studies. HER2ex20, HER2 exon 20 insertion; IC50, half-maximal inhibitory concentration; PO, orally. Source: Andrews K.L. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "684b23b3-68df-49db-801c-e734bac4933b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preclinical Characterization Demonstrates Desired Target Product Profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e45ef03-bfb9-40e8-a63e-e69b54f73177", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "fcdbe187-7e4a-4c4d-8172-1d511a3bd443", "evidence": "Avoiding EGFR Inhibition chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:44.288551+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "ee122dae-b951-492a-8b06-340fc17196d6", "evidence": "In Vitro Activity, HER2 AND HER2ex20 chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:44.254333+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 40, "type": "resolution", "title": "The slide highlights the 'OnTarget 2026' initiative, which serves as a strategic milestone for product approval.", "function": "plan_implementation", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 4, "textChars": 385, "nDataPoints": 0, "notes": "The slide highlights the 'OnTarget 2026' initiative, which serves as a strategic milestone for product approval.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.973+00", "seconds": 2.643, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/40", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-40", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.8, "w": 0.35, "x": 0.62, "y": 0.15 }, "kind": "callout", "text": "OnTarget 2026: MISSION: Bringing new, best-in-class medicines to patients with cancer", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5c38864-91d3-4886-93f7-ee131757a470", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.65, "x": 0.08, "y": 0.15 }, "kind": "diagram", "text": "2024: Execute on global registrational strategies; 2025: First pivotal data; 2026: First approved product", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d7e82a04-e50e-4f5d-856e-5fe833a3cf2a", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.5, "x": 0.08, "y": 0.42 }, "kind": "list", "text": "Program Status: NVL-520 (ARROS-1 study for ROS1+ NSCLC); NVL-655 (ALKOVE-1 study for ALK+ NSCLC); NVL-330 for HER2+ NSCLC; Additional Discovery Research Programs Ongoing", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "711976e3-fdea-44c0-80c7-1022e1c0c0bb", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "The Path to Patient Impact", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4635777-9ebb-4949-bb5c-6b57e0980283", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e7eee589-a76a-4c68-a0e6-8d123d9ff956", "evidence": "Chronological progression of goals from 2024 to 2026.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:09:47.973+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 40, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 41, "type": "setup", "function": "front_matter", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 2, "textChars": 47, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:09:47.551+00", "seconds": 2.148, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/41", "deck": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe", "deckAnchor": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-41", "deckJson": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json" }, "components": [ { "bbox": { "h": 0.28, "w": 0.364, "x": 0.318, "y": 0.36 }, "kind": "image", "text": "Nuvalent logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.551+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e0c436c-04d8-4180-9570-78ea77ae4d09", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.06, "y": 0.81 }, "kind": "paragraph", "text": "www.nuvalent.com\ninfo@nuvalent.com", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:09:47.551+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cc3836c3-2610-4a02-8704-80a242baa2f2", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "5c86240e-7a2f-411c-92f5-62a0c9190056", "evidence": "Nuvalent logo and contact info", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:44.392122+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 41, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 9, "to": 9, "label": "Problem", "description": "The document presents the problem of emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events in current cancer therapies." }, { "from": 10, "to": 10, "label": "Solution", "description": "The document presents Nuvalent's solution, including their innovative approach to cancer therapy and promising clinical trial results." }, { "from": 11, "to": 11, "label": "Market Sizing", "description": "The document presents the market sizing for Nuvalent's therapies, highlighting the significant commercial opportunity." }, { "from": 12, "to": 12, "label": "Product", "description": "The document presents the product details for Nuvalent's therapies, including NVL-655 and NVL-520." } ], "loops": [ { "from": 9, "to": 11, "label": "Cost Of Inaction", "description": "What are the consequences of not addressing the limitations of current cancer therapies?" }, { "from": 12, "to": 14, "label": "Mece Breakdown", "description": "How do Nuvalent's therapies address the needs of patients with cancer?" } ] }